It makes the case that the '335 patent covers claims on deuterated forms of the compound – a modification used to improve pharmacokinetic properties – that are infringed by Sun Pharma's compound.

Sun Pharma successfully removed an injunction in the US on the launch of its Leqselvi for alopecia areata, a common form of hair loss, that was sought by rival Incyte. The decision in the US Court ...